Inflammation and cancer - IV. Colorectal cancer in inflammatory bowel disease: The role of inflammation

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 287, Issue 1 50-1, 2004, Pages

  Itzkowitz, Steven H ^a   Yio, Xianyang ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Animal models; Colitis; Colorectal cancer; Inflammatory bowel disease; Oxidative stress

Indexed keywords

BETA 2 MICROGLOBULIN; DNA; GLUTATHIONE PEROXIDASE; GUANINE NUCLEOTIDE BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 2; MESALAZINE; NERVE CELL ADHESION MOLECULE; PROSTAGLANDIN SYNTHASE; PROTEIN P53; RAG2 PROTEIN; REACTIVE OXYGEN METABOLITE; STEROID; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANSFORMING GROWTH FACTOR BETA1;

CANCER INHIBITION; CANCER RISK; COLON CARCINOGENESIS; COLON CROHN DISEASE; COLORECTAL CANCER; ENZYME INHIBITION; EXCISION REPAIR; HUMAN; INFLAMMATION; KNOCKOUT MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS;

ANIMALS; CHRONIC DISEASE; COLITIS; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATORY BOWEL DISEASES; LOSS OF HETEROZYGOSITY;

EID: 3042599473     PISSN: 01931857     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpgi.00079.2004     Document Type: Review

References (89)

1. Agoff SN, Brentnall TA, Crispin DA, Taylor SL, Raaka S, Haggitt RC, Reed MW, Afonina IA, Rabinovitch PS, Stevens AC, Feng Z, and Bronner MP. The role of cyclooxygenase 2 in ulcerative colitis-associated neoplasia. Am J Pathol 157: 737-745, 2000.
2. Ahn B and Ohshima H. Suppression of intestinal polyposis in Apc-(Min/+) mice by inhibiting nitric oxide production. Cancer Res 61: 8357-8360, 2001.
3. WAF1/CIP1 expression in ulcerative colitis. Mod Pathol 12: 604-611, 1999.
4. Aust DE, Terdiman JP, Willenbucher RF, Chang CG, Molinaro-Clark A, Baretton GB, Loehrs U, and Waldman FM. The APC/β-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer 94: 1421-1427, 2002.
5. Balish E and Warner T. Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. Am J Pathol 160: 2253-2257, 2002.
6. Beck PL, Xavier R, Wong J, Ezedi I, Mashimo H, Mizoguchi A, Mizoguchi E, Bhan AK, and Podolsky DK. Paradoxical roles of different nitric oxide synthase isoforms in colonic injury. Am J Physiol Gastrointest Liver Physiol 286: G137-G147, 2004.
7. + TH1-like responses. J Clin Invest 98: 1010-1020, 1996.
8. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, and Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58: 5248-5257, 1998.
9. Brentnall TA, Crispin DA, Bronner MP, Cherian SP, Hueffed M, Rabinovitch PS, Rubin CE, Haggitt RC, and Boland CR. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res 56: 1237-1240, 1996.
10. Brentnall TA, Crispin DA, Rabinovitch PS, Haggitt RC, Rubin CE, Stevens AC, and Burmer GC. Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology 107: 369-378, 1994.
11. Brentnall TA, Rubin CE, Crispin DA, Stevens A, Batchelor RH, Haggitt RC, Bronner MP, Evans JP, McCahill LE, Bilir N, Boland CR, and Rabinovitch PS. A germline substitution in the human MSH2 gene is associated with high-grade dysplasia and cancer in ulcerative colitis. Gastroenterology 109: 151-155, 1995.
12. Bull AW. The role of peroxisome proliferator-activated receptor gamma in colon cancer and inflammatory bowel disease. Arch Pathol Lab Med 127: 1121-1123, 2003.
13. Burmer GC, Rabinovitch PS, Haggitt RC, Crispin DA, Brentnall TA, Kolli VR, Stevens AC, and Rubin CE. Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology 103: 1602-1610, 1992.
14. Bus PJ, Nagtegaal ID, Verspaget HW, Lamers CB, Geldof H, Van Krieken JH, and Griffioen G. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther 13: 1397-1402, 1999.
15. Chang CL, Marra G, Chauhan DP, Ha HT, and Chang DK, Ricciardiello L, Randolph A, Carethers JM, Boland CR. Oxidative stress inactivates the human DNA mismatch repair system. Am J Physiol Cell Physiol 283: C148-C154, 2002.
16. Chen R, Rabinovitch PS, Crispin DA, Emond MJ, Koprowicz KM, Bronner MP, and Brentnall TA. DNA fingerprinting abnormalities can distinguish ulcerative colitis patients with dysplasia and cancer from those who are dysplasia/cancer-free. Am J Pathol 162: 665-672, 2003.
17. Chu FF, Esworthy RS, Chu PG, Longmate JA, Huycke MM, Wilczynski S, and Doroshow JH. Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 Genes. Cancer Res 64: 962-968, 2004.
18. Cooper HS, Everley L, Chang WC, Preiffer G, Lee B, Murthy S, and Clapper ML. The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. Gastroenterology 121: 1407-1416, 2001.
19. Cooper HS, Murthy S, Kido K, Yoshitake H, and Flanigan A. Dysplasia and cancer in the dextran sulfate sodium mouse colitis model: relevance to colitis-associated neoplasia in the human. Carcinogenesis 21: 757-768, 2000.
20. Coussens LM and Werb Z. Inflammation and cancer. Nature 420: 860-867, 2002.
21. Croog VJ, Ullman TA, and Itzkowitz SH. Chemoprevention of colorectal cancer in ulcerative colitis. Int J Colorectal Dis 18: 392-400, 2003.
22. Crowell JA, Steele VE, Sigman CC, and Fay JR. Is inducible nitric oxide synthase a target for chemoprevention? Mol Cancer Ther 2: 815-823, 2003.
23. D'Inca R, Cardin R, Benazzato L, Angriman I, Martines D, and Sturniolo GC. Oxidative DNA damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. Inflamm Bowel Dis 10: 23-27, 2004.
24. Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, Colombel JF, Auwerx J, Pettersson S, and Desreumaux P. Impaired expression of peroxisome proliferator-activated receptor γ in ulcerative colitis. Gastroenterology 124: 1265-1276, 2003.
25. Eaden J, Abrams K, Ekbom A, Jackson E, and Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 14: 145-153, 2000.
26. Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS, and Doetschman T. Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 59: 3379-3386, 1999.
27. Engle SJ, Ormsby I, Pawlowski S, Boivin GP, Croft J, Balish E, and Doetschman T. Elimination of colon cancer in germ-free transforming growth factor β1-deficient mice. Cancer Res 62: 6362-6326, 2002.
28. + regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am J Pathol 162: 691-702, 2003.
29. + regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res 63: 6042-6250, 2003.
30. Erlinger TP, Platz EA, Rifai N, and Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 291: 585-590, 2004.
31. Fleisher AS, Esteller M, Harpaz N, Leytin A, Rashid A, Xu Y, Liang J, Stine OC, Yin J, Zou TT, Abraham JM, Kong D, Wilson KT, James SP, Herman JG, and Meltzer SJ. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res 60: 4864-4868, 2000.
32. Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, Gaspar C, van Es JH, Breukel C, Wiegant J, Giles RH, and Clevers H. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat Cell Biol 3: 433-438, 2001.
33. Gasche C, Chang CL, Rhees J, Goel A, and Boland CR. Oxidative stress increases frameshift mutations in human colorectal cancer cells. Cancer Res 61: 7444-7448, 2001.
34. Gupta RA, DuBois RN, and Wallace MC. New avenues for the prevention of colorectal cancer: targeting cyclo-oxygenase-2 activity. Best Pract Res Clin Gastroenterol 16: 945-956, 2002.
35. Hegazi RA, Mady HH, Melhem MF, Sepulveda AR, Mohi M, and Kandil HM. Celecoxib and rofecoxib potentiate chronic colitis and premalignant changes in interleukin 10 knockout mice. Inflamm Bowel Dis 9: 230-236, 2003.
36. Hermiston ML and Gordon JI. Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science 270: 1203-1207, 1995.
37. Hibi T, Ogata H, and Sakuraba A. Animal models of inflammatory bowel disease. J Gastroenterol 37: 409-417, 2002.
38. Hisamatsu T, Watanabe M, Ogata H, Ezaki T, Hozawa S, Ishii H, Kanai T, and Hibi T. Interferon-inducible gene family 1-8U expression in colitis-associated colon cancer and severely inflamed mucosa in ulcerative colitis. Cancer Res 59: 5927-5931, 1999.
39. Hofseth LJ, Khan MA, Ambrose M, Nikolayeva O, Xu-Welliver M, Kartalou M, Hussain SP, Roth RB, Zhou X, Mechanic LE, Zurer I, Rotter V, Samson LD, and Harris CC. The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest 112: 1887-1894, 2003.
40. Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink DA, Appella E, and Harris CC. Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci USA 100: 143-148, 2003.
41. Hokari R, Kato S, Matsuzaki K, Kuroki M, Iwai A, Kawaguchi A, Nagao S, Miyahara T, Itoh K, Sekizuka E, Nagata H, Ishii H, and Miura S. Reduced sensitivity of inducible nitric oxide synthase-deficient mice to chronic colitis. Free Radic Biol Med 31: 153-163, 2001.
42. Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, and Porschen R. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res 58: 3942-3945, 1998.
43. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, Swenberg JA, Marrogi AJ, and Harris CC. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 60: 3333-3337, 2000.
44. Hussain SP, Hofseth LJ, and Harris CC. Radical causes of cancer. Nature Rev Cancer 276: 276-285, 2003.
45. Issa JP, Ahuja N, Toyota M, Bronner MP, and Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res 61: 3573-3577, 2001.
46. Itzkowitz SH. Cancer prevention in patients with inflammatory bowel disease. Gastroenterol Clin North Am 31: 1133-1144, 2002.
47. Itzkowitz SH and Harpaz N. Diagnosis and management of dysplasia in patients with inflammatory bowel disease. Gastroenterology 126: 2004. In press.
48. Jass JR, Whitehall VL, Young J, and Leggett BA. Emerging concepts in colorectal neoplasia. Gastroenterology 123: 862-876, 2002.
49. Kado S, Uchida K, Funabashi H, Iwata S, Nagata Y, Ando M, Onoue M, Matsuoka Y, Ohwaki M, and Morotomi M. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor β chain and p53 double-knockout mice. Cancer Res 61: 2395-2398, 2001.
50. Kimura H, Hokari R, Miura S, Shigematsu T, Hirokawa M, Akiba Y, Kurose I, Higuchi H, Fujimori H, Tsuzuki Y, Serizawa H, and Ishii H. Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut 42: 180-187, 1998.
51. Kohonen-Corish MR, Daniel JJ, te Riele H, Buffinton GD, and Dahlstrom JE. Susceptibility of Msh2-deficient mice to inflammation-associated colorectal tumors. Cancer Res 62: 2092-2097, 2002.
52. Kullmann F, Messmann H, Alt M, Gross V, Bocker T, Scholmerich J, and Ruschoff J. Clinical and histopathological features of dextran sulfate sodium induced acute and chronic colitis associated with dysplasia in rats. Int J Colorectal Dis 16: 238-46, 2001.
53. Marnett LJ. Oxyradicals and DNA damage. Carcinogenesis 21: 361-370, 2000.
54. Mathy C, Schneider K, Chen YY, Varma M, Terdiman JP, and Mahadevan U. Gross versus microscopic pancolitis and the occurrence of neoplasia in ulcerative colitis. Inflamm Bowel Dis 9: 351-355, 2003.
55. McKenzie SJ, Baker MS, Buffinton GD, and Doe WF. Evidence of oxidant-induced injury to epithelial cells during inflammatory bowel disease. J Clin Invest 98: 136-141, 1996.
56. McKenzie SM, Doe WF, and Buffinton GD. 5-aminosalicylic acid prevents oxidant mediated damage of glyceraldehyde-3-phosphate dehydrogenase in colon epithelial cells. Gut 44: 180-185, 1999.
57. Moore KW, de Waal Malefyt R, Coffman RL, and O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 19: 683-765, 2001.
58. Niho N, Takahashi M, Kitamura T, Shoji Y, Itoh M, Noda T, Sugimura T, and Wakabayashi K. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 63: 6090-6095, 2003.
59. Noffsinger A, Kretschmer S, Belli J, Fogt F, and Fenoglio-Preiser C. Microsatellite instability is uncommon in intestinal mucosa of patients with Crohn's disease. Dig Dis Sci 45: 378-384, 2000.
60. Noffsinger AE, Belli JM, Fogt F, Fischer J, Goldman H, and Fenoglio-Preiser CM. A germline hMSH2 alteration is unrelated to colonic microsatellite instability in patients with ulcerative colitis. Hum Pathol 30: 8-12, 1999.
61. Okayasu I, Yamada M, Mikami T, Yoshida T, Kanno J, and Ohkusa T. Dysplasia and carcinoma development in a repeated dextran sulfate sodium-induced colitis model. J Gastroenterol Hepatol 17: 1078-1083, 2002.
62. O'Mahony L, Feeney M, O'Halloran S, Murphy L, Kiely B, Fitzgibbon J, Lee G, O'Sullivan G, Shanahan F, and Collins JK. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 15: 1219-1225, 2001.
63. O'Sullivan JN, Bronner MP, Brentnall TA, Finley JC, Shen WT, Emerson S, Emond MJ, Gollahon KA, Moskovitz AH, Crispin DA, Potter JD, and Rabinovitch PS. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 32: 280-284, 2002.
64. Pinczowski D, Ekbom A, Baron J, Yuen J, and Adami HO. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology 107: 117-120, 1994.
65. Rabinovitch PS, Dziadon S, Brentnall TA, Emond MJ, Crispin DA, Haggitt RC, and Bronner MP. Pancolonic chromosomal instability precedes dysplasia and cancer in ulcerative colitis. Cancer Res 59: 5148-5153, 1999.
66. Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z, and Podolsky DK. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Gut 36: 718-723, 1995.
67. Rachmilewitz D, Stamler JS, Karmeli F, Mullins ME, Singel DJ, Loscalzo J, Xavier RJ, and Podolsky DK. Peroxynitrite-induced rat colitis-a new model of colonic inflammation. Gastroenterology 105: 1681-1688, 1993.
68. Redston MS, Papadopoulos N, Caldas C, Kinzler KW, and Kern SE. Common occurrence of APC and K-ras gene mutations in the spectrum of colitis-associated neoplasias. Gastroenterology 108: 383-392, 1995.
69. Ricciardiello L, Baglioni M, Giovannini C, Pariali M, Cenacchi G, Ripalti A, Landini MP, Sawa H, Nagashima K, Frisque RJ, Goel A, Boland CR, Tognon M, Roda E, and Bazzoli F. Induction of chromosomal instability in colonic cells by the human polyomavirus JC virus. Cancer Res 63: 7256-7262, 2003.
70. Ritland SR, Leighton JA, Hirsch RE, Morrow JD, Weaver AL, and Gendler SJ. Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse. Clin Cancer Res 5: 855-863, 1999.
71. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, Scholmerich J, and Gross V. Nuclear factor κB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 115: 357-369, 1998.
72. Rubin CE, Haggitt RC, Burmer GC, Brentnall TA, Stevens AC, Levine DS, Dean PJ, Kimmey M, Perera DR, and Rabinovitch PS. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 103: 1611-1620, 1992.
73. αi2-deficient mice. Nat Genet 10: 143-150, 1995.
74. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, Williams C, Price A, Talbot I, and Forbes A. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 126: 451-459, 2004.
75. Santini V, Kantarjian HM, and Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 134: 573-586, 2001.
76. Sato F, Harpaz N, Shibata D, Xu Y, Yin J, Mori Y, Zou TT, Wang S, Desai K, Leytin A, Selaru FM, Abraham JM, and Meltzer SJ. Hypermethylation of the p14(ARF) gene in ulcerative colitis-associated colorectal carcinogenesis. Cancer Res 62: 1148-1151, 2002.
77. Seril DN, Liao J, Ho KL, Yang CS, and Yang GY. Inhibition of chronic ulcerative colitis-associated colorectal adenocarcinoma development in a murine model by N-acetylcysteine. Carcinogenesis 23: 993-1001, 2002.
78. Seril DN, Liao J, Yang GY, and Yang CS. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 24: 353-362, 2003.
79. Shattuck-Brandt RL, Varilek GW, Radhika A, Yang F, Washington MK, and DuBois RN. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology 118: 337-345, 2000.
80. 2-microglobulin-deficient mouse. Cancer Res 61: 6912-6917, 2001.
81. Steele VE, Hawk ET, Viner JL, and Lubet RA. Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer. Mutat Res 523-524: 137-144, 2003.
82. Sturlan S, Oberhuber G, Beinhauer BG, Tichy B, Kappel S, Wang J, and Rogy MA. Interleukin-10-deficient mice and inflammatory bowel disease associated cancer development. Carcinogenesis 22: 665-671, 2001.
83. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, Flanigan A, Murthy S, Lazar MA, and Wu GD. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Invest 104: 383-389, 1999.
84. Tarmin L, Yin J, Harpaz N, Kozam M, Noordzij J, Antonio LB, Jiang HY, Chan O, Cymes K, and Meltzer SJ. Adenomatous polyposis coli gene mutations in ulcerative colitis-associated dysplasias and cancers versus sporadic colon neoplasms. Cancer Res 55: 2035-2038, 1995.
85. Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB, and Issa JP. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96: 8681-8686, 1999.
86. Umetani N, Sasaki S, Watanabe T, Shinozaki M, Matsuda K, Ishigami H, Ueda E, and Muto T. Genetic alterations in ulcerative colitis-associated neoplasia focusing on APC, K-ras gene and microsatellite instability. Jpn J Cancer Res 90: 1081-1087, 1999.
87. Willenbucher RF, Aust DE, Chang CG, Zelman SJ, Ferrell LD, Moore DH 2nd, and Waldman FM. Genomic instability is an early event during the progression pathway of ulcerative-colitis-related neoplasia. Am J Pathol 154: 1825-1830, 1999.
88. Yamamoto Y and Gaynor RB. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J Clin Invest 107: 135-142, 2001.
89. Yin J, Harpaz N, Tong Y, Huang Y, Laurin J, Greenwald BD, Hontanosas M, Newkirk C, and Meltzer SJ. p53 point mutations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology 104: 1633-1639, 1993.